Volociximab Biosimilar Monoclonal Antibody (Integrin α5) for Research
Cat No.: GMP-Bios-INN-1049
Anti-ITGA5 therapeutic antibody (Pre-made Volociximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Volociximab (also known as M2) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1049-1mg | 1mg | 2101.8 |
| GMP-Bios-INN-1049-10mg | 10mg | |
| GMP-Bios-INN-1049-100mg | 100mg | |
| GMP-Bios-INN-1049-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Volociximab Biosimilar, Whole Mab, Anti-Itga5 Antibody: Anti-CD49eRA/VLA-5/VLA5A therapeutic antibody |
| INN Name | Volociximab |
| Target | ITGA5 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG4 - nd |
| VD LC | IgG4 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | 0 |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |

